SCHEMBL10045860

SCHEMBL10045860

CNC(=O)C(CS)NC(C)=O

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.63
MAPT P10636 1/20 0.63
THRB P10828 1/20 0.63
ALOX15 P16050 1/20 0.63
NFKB1 P19838 1/20 0.63
PTGS2 P35354 1/20 0.63
THPO P40225 1/20 0.63
RECQL P46063 1/20 0.63
BLM P54132 1/20 0.63
SMN1; SMN2 Q16637 1/20 0.63
BMP1 P13497 2/20 0.44
ACE P12821 1/20 0.42
ALDH1A1 P00352 1/20 0.41
MMP1 P03956 5/20 0.35
MMP9 P14780 4/20 0.34
MMP2 P08253 2/20 0.34
MMP8 P22894 2/20 0.34
MMP3 P08254 2/20 0.34
FNTA P49354 1/20 0.33
FNTB P49356 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13299209 1.00 KDM4E (0.63) KDM4EMAPTTHRBALOX15NFKB1
SCHEMBL12632549 1.00 KDM4E (0.63) KDM4EMAPTTHRBALOX15NFKB1
SCHEMBL20328839 0.85 KDM4E (0.52) KDM4EMAPTTHRBALOX15NFKB1
SCHEMBL4990551 0.84 BMP1 (0.45) KDM4EMAPTTHRBALOX15NFKB1
SCHEMBL17623527 0.83 KDM4E (0.48) KDM4EMAPTTHRBALOX15NFKB1
SCHEMBL4704123 0.83 BMP1 (0.47) KDM4EMAPTTHRBALOX15NFKB1
SCHEMBL4988312 0.83 BMP1 (0.44) KDM4EMAPTTHRBALOX15NFKB1
SCHEMBL12354387 0.81 KDM4E (0.61) KDM4EMAPTTHRBALOX15NFKB1
SCHEMBL928644 0.81 KDM4E (0.61) KDM4EMAPTTHRBALOX15NFKB1
SCHEMBL27447128 0.81 KDM4E (0.61) KDM4EMAPTTHRBALOX15NFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024092256-A2 PEPTIDE-ANTISENSE OLIGONUCLEOTIDES AND THEIR USE FOR TREATMENT OF NEURODEGENERATIVE DISORDERS EISAI R&D MANAGEMENT CO., LTD. (JP) 2024-05-02 WO disclosed
WO-2022109058-A1 NUCLEASES COMPRISING CELL PENETRATING PEPTIDE SEQUENCES ENTRADA THERAPEUTICS, INC. (US) 2022-05-27 WO disclosed
US-10329558-B2 Method for producing compound containing heterocycle THE UNIVERSITY OF TOKYO (JP) 2019-06-25 US disclosed
US-10197567-B2 Azoline compound and azole compound library and method for producing same THE UNIVERSITY OF TOKYO (JP) 2019-02-05 US disclosed
US-20170318932-A1 METHOD FOR STRAIGHTENING KERATINOUS FIBERS USING HEATING MEANS AND MALIC ACID L'OREAL (FR) 2017-11-09 US disclosed
US-9757318-B2 Process for relaxing keratin fibres L'OREAL (FR) 2017-09-12 US disclosed
EP-2029095-B1 PROCESS FOR STRAIGHTENING KERATIN FIBRES WITH A HEATING MEANS AND DENATURING AGENTS L'ORÉAL (FR) 2017-08-30 EP disclosed
US-9743736-B2 Method for straightening human hair fibers using heating means and malic acid L'OREAL (FR) 2017-08-29 US disclosed
US-9676907-B2 Methods and systems of graft polymerization on a functionalized substrate ASPEN RESEARCH CORPORATION (US) 2017-06-13 US disclosed
US-20170035175-A1 METHOD FOR STRAIGHTENING HUMAN HAIR FIBERS USING HEATING MEANS AND MALIC ACID L'OREAL (FR) 2017-02-09 US disclosed
US-7879827-B2 such as 5-amino-2-(2-Acetylamino-3-mercapto-propionyloxy)-benzoic acid, useful for the treatment of gastrointestinal disorders such as inflammatory bowel disease and irritable bowel syndrome, and for the prevention/treatment of colon cancer ANTIBE THERAPEUTICS INC. (CA) 2011-02-01 US disclosed
US-7879827-B2 such as 5-amino-2-(2-Acetylamino-3-mercapto-propionyloxy)-benzoic acid, useful for the treatment of gastrointestinal disorders such as inflammatory bowel disease and irritable bowel syndrome, and for the prevention/treatment of colon cancer ANTIBE THERAPEUTICS INC. (CA) 2011-02-01 US disclosed
US-20090233886-A1 DERIVATIVES OF 4- OR 5-AMINOSALICYLIC ACID ANTIBE THERAPEUTICS INC. (CA) 2009-09-17 US disclosed
US-20090233886-A1 DERIVATIVES OF 4- OR 5-AMINOSALICYLIC ACID ANTIBE THERAPEUTICS INC. (CA) 2009-09-17 US disclosed
US-7498355-B2 Derivatives of 4- or 5-aminosalicylic acid ANTIBE THERAPEUTICS INC. (CA) 2009-03-03 US disclosed
US-7498355-B2 Derivatives of 4- or 5-aminosalicylic acid ANTIBE THERAPEUTICS INC. (CA) 2009-03-03 US disclosed
US-20080207564-A1 Derivaitves of 4-Or 5-Aminosalicylic Acid ANTIBE THERAPEUTICS INC. (CA) 2008-08-28 US disclosed
US-20080207564-A1 Derivaitves of 4-Or 5-Aminosalicylic Acid ANTIBE THERAPEUTICS INC. (CA) 2008-08-28 US disclosed
US-20070197479-A1 Derivatives of 4- or 5-aminosalicylic acid ANTIBE THERAPEUTICS INC. (CA) 2007-08-23 US disclosed
US-20070197479-A1 Derivatives of 4- or 5-aminosalicylic acid ANTIBE THERAPEUTICS INC. (CA) 2007-08-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10329558-B2 Method for producing compound containing heterocycle VIP, DNPEP, PREP KDM4E 2288/4885MAPT 4580/4885THRB 4520/4885
US-20080207564-A1 Derivaitves of 4-Or 5-Aminosalicylic Acid CBS, SI, TST KDM4E 422/4885MAPT 2229/4885THRB 4276/4885
US-20170035175-A1 METHOD FOR STRAIGHTENING HUMAN HAIR FIBERS USING HEATING MEANS AND MALIC ACID KRT18, HOGA1, CYP11A1 KDM4E 1028/4885MAPT 482/4885THRB 2472/4885
US-20090233886-A1 DERIVATIVES OF 4- OR 5-AMINOSALICYLIC ACID CBS, SI, APC KDM4E 739/4885MAPT 3407/4885THRB 4135/4885
US-10197567-B2 Azoline compound and azole compound library and method for producing same PEPD, DAO, ANPEP KDM4E 3568/4885MAPT 4136/4885THRB 812/4885
US-20170318932-A1 METHOD FOR STRAIGHTENING KERATINOUS FIBERS USING HEATING MEANS AND MALIC ACID KRT18, HOGA1, KLK5 KDM4E 963/4885MAPT 374/4885THRB 3291/4885
US-20070197479-A1 Derivatives of 4- or 5-aminosalicylic acid CBS, SI, APC KDM4E 739/4885MAPT 3407/4885THRB 4135/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.